About Us

Exploring the benefits of Keratin Proteins & Peptides


Our mission is to explore the therapeutic benefits of the keratin molecule—as it is the foundation of organic tissue repair—and provide our products to those who are in greatest need.


Our passions are keratin proteins and peptides, of which we currently manufacture proprietary fractionations that are incorporated into our prescription-only products.

Molecular Biologicals

Founded in 2015, Molecular Biologicals is a biotechnology company that provides prescription-only keratin products for Dermatological, Regenerative and Woundcare markets worldwide. Our company is based on a therapeutic keratin platform developed from years of research and supported by patented proprietary manufacturing and processing technologies.

Research & Development

Molecular Biologicals is currently investigating the use of Replicine™ Bioactive Keratin in specific wound types and formulations. We are actively involved in expanding our pipeline of products in high priority access areas with obvious unmet needs, like orphan diseases.

Keroxx, a flowable advanced-wound matrix containing the active ingredient Replicine™ Bioactive Keratin will be available in 2021.

Our Team

Kevin Combs - CEO
Entrepreneur and corporate executive with a successful track record of building operating companies to produce outsized value, while maintaining core values of integrity, passionate pursuit of purpose, and consistent sustainability.

  • Created +$2B USD in returns to investors as a founder/Operator, heavily focused on pharma & biotech.
  • Commercial lead for Lanoxin Canada post 2001 GlaxoWellcome acquisition; Acquisition of commercial rights to Cycloset 2005, sold to Valeant, sold PBM Pharma 2014, sourced/closed substantial position in Avexis in 2014 leading to ultimate 2016 Nasdaq listing and $8.78B sale to Novartis in 2018.
  • Extensive corporate experience at GSK, AZ/MedImmune, and Novartis Vaccines.
  • Angel investor and board member for US early stage technology companies.

Lee Drosdak
Accomplished sales manager with experience hiring and training teams of direct reports to implement customer engagement plans. Well documented history of leading pre and post launch sales/training activities for 15 new pharmaceutical brands to achieve award winning results.

Joe Marchant Jr.
Joe is Vice President for Molecular Biologicals and a member of the Corporate Executive Team. He is responsible for supporting MB's strategy by leading the Market Access Department in matters such as business development with CMS, National and Regional payor groups. Joe joined MB in May 2020. Prior to MB Joe spent 23 years at GlaxoSmithKline working in several divisions within the company including Payor Access, Government Affairs, DOD/VA, Vaccines and General Pharmaceuticals. Joe was a proud member of the United States Airforce serving in the US as well as Europe. Joe holds a BS degree from the University of South Carolina.